MDMA-Assisted Therapy for Neuropathic Pain: Mechanisms, Evidence, and the Case for Dedicated Clinical Trials: A Narrative Review
Zenodo (CERN European Organization for Nuclear Research) August 21, 2026 Ivan Temprado-Ordiaz
3,4-Methylenedioxymethamphetamine (MDMA) has emerged as a promising therapeutic candidate for treatment-resistant neuropathic pain, offering a paradigm shift from transient palliative symptom masking toward disease-modifying neuroplastic reorganization. Preclinical and clinical evidence demonstrates that MDMA operates through an integrated, multi-tiered neurobiological cascade: presynaptic...